See important information below about the risk of hepatitis B virus reactivation.

MODEL

Getting the emotional support you need

Since being diagnosed with hep C, you may have experienced some difficult emotions. You may find it helpful to reach out to your circle of support and share your story with others.

Telling others about your hep C

The decision to tell friends and family about your hep C is a personal one. How much they actually know about hep C may affect how they interact with you. Learn as much as you can about hep C, so you can talk openly about it with your loved ones.

 

Here are some things you may want to bring up:

  • Hep C is not spread by hugging, kissing, or shaking hands

  • There are ways to manage hep C infection and there are treatments that can cure it. Cure means the hep C virus is not detected in the blood when measured 3 months after treatment is completed

  • Hep C infection can cause liver damage slowly over time, even without symptoms

Your family and friends...who needs to know?

When you have hep C, you’ll want to tell the people you’re closest to. These may include:

  Your spouse or partner
  Your family
  Your doctors
  Your dentist
  Anyone you may have shared needles with
  Sexual partners

Your hep C health care team is here to help

During treatment, you may have more than one health care provider to support you on your journey. To learn more about people who might be part of your hep C health care team, click below.

YOUR HEP C HEALTH CARE TEAM
YOUR HEP C HEALTH CARE TEAM

Reach out

You may also find it rewarding to reach out to local advocacy groups and help others on their journey.

Here’s a list of some organizations and resources to get you started:

What steps to take after your hep C treatment

AFTER HEP C TREATMENT

What is ZEPATIER?

ZEPATIER® (elbasvir and grazoprevir) is a prescription medicine used to treat chronic (long‑lasting) hepatitis C (hep C) genotypes 1 or 4 infection in adults. ZEPATIER may sometimes be given with another medicine called ribavirin.

Important Safety Information

Before starting treatment with ZEPATIER® (elbasvir and grazoprevir), your health care provider will do blood tests to check for hepatitis B virus infection. If you have ever had hepatitis B virus infection, the hepatitis B virus could become active again during or after treatment of hep C virus infection with ZEPATIER. This is called hepatitis B virus reactivation, and it may cause serious liver problems including liver failure and death. Your health care provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop taking ZEPATIER.

ZEPATIER is not for people with certain liver problems. Before taking ZEPATIER, tell your health care provider about all of your medical conditions, including if you have ever had hepatitis B virus infection or have liver problems other than hep C. Also tell your health care provider if you have ever taken any medicine for hep C, have HIV, or have had or are waiting for a liver transplant.

If you are nursing, pregnant, or trying to get pregnant, tell your health care provider. It is not known if ZEPATIER® (elbasvir and grazoprevir) will harm your unborn baby or pass to your baby through breast milk. If you take ZEPATIER with ribavirin, be sure you read the Medication Guide for ribavirin, especially the important pregnancy, contraception, and infertility information.

Tell your health care provider about all of the medicines you take. ZEPATIER may affect how other medicines work, and other medicines may affect how ZEPATIER works. Some medicines cannot be taken with ZEPATIER. Your health care provider can tell you if it is safe to take ZEPATIER with other medicines.

ZEPATIER may cause increases in your liver-related blood tests, which could be a sign of serious liver problems. Your health care provider will do blood tests to check your liver before and during treatment with ZEPATIER. Tell your health care provider right away if you get any of the following symptoms or if they get worse during treatment with ZEPATIER: loss of appetite, nausea and vomiting, feeling tired or weak, yellowing of your skin or eyes, or color changes in your stool.

In clinical studies, common side effects of ZEPATIER included: feeling tired, headache, and nausea. When ZEPATIER was taken with ribavirin, common side effects also included low red blood cell counts (called anemia).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.

Before taking ZEPATIER® (elbasvir and grazoprevir), please read the accompanying Patient Information, including information about the risk of the hepatitis B virus (HBV) becoming active again in patients who have ever had HBV infection, and discuss it with your doctor. The Prescribing Information also is available.

Questions about ZEPATIER?
Call 844-ZEPATIER (844‑937‑2843)
for more information.




Please orient your device to the portrait position to return to the site